



EV816191962US

Express Mail No.: EV 816191962 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Jerome B. Zeldis, et al.
of

Application No.: 10/820,397

Filed: April 8, 2004

For: METHODS FOR TREATMENT
OF COGNITIVE AND
MENOPAUSAL DISORDERS
WITH D-THREO
METHYLPHENIDATE

Confirmation No.: 8455

Art Unit: 1614

Examiner: Raymond J. Henley, III

Attorney Docket No.: CELG-0422

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.
§ 1.555**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.555 to inform the Patent and Trademark Office of all information coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for the Patent Owner direct the Examiner's attention to the information listed on the attached List of References Cited by Applicant. The Patent Owner makes no representation that any of the items are material, enabled references or prior art to the claims under reexamination.

Copies of items 501-505 are submitted herewith.

Items 501-505 are documents from a pending litigation involving U.S. Patent No. 5,908,850 ("the '850 patent") directed to somewhat similar subject matter as that of the present application. The Patent Owner is filing the instant Information Disclosure Statement to disclose the substance of that litigation to the PTO.

Item 504 has been redacted consistent with the terms of a Protective Order in the litigation. A non-redacted version of Item 504 has been submitted to the PTO, under seal, in a concurrently filed Information Disclosure Statement.

The Patent Owner respectfully requests that the Examiner review the listed items and that they be made of record in the present application.

The Patent Owner believes no fee is due in connection with this disclosure. However, the Commissioner is hereby authorized to charge any required fee(s), or credit any overpayment, to Woodcock Washburn Deposit Account No. 23-3050.

Respectfully submitted,




Walter C. Frank

Reg. No. 52,911

Date: November 3, 2006

Woodcock Washburn LLP
One Liberty Place, 46th Floor
Philadelphia, PA 19148
Telephone: 215-568-3100

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. CELG-0422	APPLICATION NO. 10/820,397
	APPLICANT Jerome B. Zeldis, et al.	
	FILING DATE April 8, 2004	GROUP 1614



OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/D.S./	501	Complaint, filed August 19, 2004, Civil Action No. 04-4030(SRC), <i>Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc.</i>
	502	Answer and Counterclaim of Defendant Teva Pharmaceuticals USA, Inc., filed November 9, 2004, Civil Action No. 04-4030(SRC), <i>Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc.</i>
	503	Plaintiffs' Reply to Defendant's Counterclaim, filed November 29, 2004, Civil Action No. 04-4030(SRC), <i>Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc.</i>
	504	Redacted Amended Answer and Counterclaims of Defendant Teva Pharmaceuticals USA, Inc., filed November 9, 2005, Civil Action No. 04-4030(SRC), <i>Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc.</i>
/D.S./	505	Plaintiffs' Reply to Defendant's Amended Counterclaims, filed December 5, 2005, Civil Action No. 04-4030(SRC), <i>Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc.</i>

EXAMINER	/Darryl Sutton/	DATE CONSIDERED	03/14/2008
----------	-----------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.